Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tisagenlecleucel
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Undisclosed
Deal Type : Agreement
Details : Novartis has entered into an agreement with Cell Therapies to manufacture Kymriah at their production facility within the Peter MacCallum Cancer Centre in Melbourne.
Product Name : Kymriah
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
January 28, 2020
Lead Product(s) : Tisagenlecleucel
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Undisclosed
Deal Type : Agreement